Apollo Endosurgery, Inc. (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. purchased 185,157 shares of the stock in a transaction on Friday, December 22nd. The stock was bought at an average cost of $4.85 per share, for a total transaction of $898,011.45. Following the completion of the acquisition, the insider now owns 2,410,141 shares in the company, valued at $11,689,183.85. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Stonepine Capital, L.P. also recently made the following trade(s):

  • On Wednesday, December 20th, Stonepine Capital, L.P. bought 45,434 shares of Apollo Endosurgery stock. The shares were acquired at an average cost of $4.50 per share, for a total transaction of $204,453.00.

Shares of Apollo Endosurgery, Inc. (NASDAQ APEN) opened at $5.10 on Friday. Apollo Endosurgery, Inc. has a 52-week low of $3.55 and a 52-week high of $21.88. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.54 and a quick ratio of 2.00. The firm has a market cap of $89.59, a P/E ratio of -0.23 and a beta of 0.46.

A number of institutional investors have recently modified their holdings of the business. Stonepine Capital Management LLC acquired a new stake in Apollo Endosurgery in the third quarter valued at approximately $11,067,000. King Luther Capital Management Corp acquired a new stake in Apollo Endosurgery in the third quarter valued at approximately $2,567,000. Russell Investments Group Ltd. acquired a new stake in Apollo Endosurgery in the third quarter valued at approximately $1,288,000. Woodmont Investment Counsel LLC acquired a new stake in Apollo Endosurgery in the third quarter valued at approximately $220,000. Finally, JPMorgan Chase & Co. acquired a new stake in Apollo Endosurgery in the third quarter valued at approximately $119,000. Hedge funds and other institutional investors own 23.67% of the company’s stock.

A number of research analysts recently issued reports on the stock. Northland Securities reissued a “buy” rating and issued a $12.00 price objective on shares of Apollo Endosurgery in a research note on Tuesday, November 28th. Zacks Investment Research raised shares of Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.44.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/12/24/stonepine-capital-l-p-purchases-185157-shares-of-apollo-endosurgery-inc-apen-stock.html.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.